Xeris Biopharma Holdings Business Summary

Xeris Biopharma Holdings, Inc. (XERS) is a commercial-stage biopharmaceutical company that generates revenue through the direct sale of proprietary specialty therapeutics and the out-licensing of its formulation technology platforms, XeriSol and XeriJect. The company’s primary business segments are focused on endocrinology and neurology, anchored by three key commercial products: Recorlev for Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis. As of early 2026, Xeris has transitioned into a high-growth specialty pharma platform, reporting preliminary 2025 revenues of approximately $292 million, driven largely by the rapid market adoption of Recorlev. The company competes directly with Zealand Pharma (Zegalogue), Eli Lilly, Novo Nordisk, and Recordati Rare Diseases. Within this landscape, Xeris distinguishes itself as a market leader in the ready-to-use glucagon rescue sector, where its Gvoke HypoPen maintains a significant market share against legacy emergency kits. Leadership is currently spearheaded by Chief Executive Officer John P. Shannon, who assumed the role in August 2024 following a successful tenure as the company’s President and COO and previous executive experience at Baxter Healthcare and Durata Therapeutics. The executive team includes President and COO Kevin McCulloch, Chief Financial Officer Steven Pieper, and Chief Medical Officer Anh Nguyen, MD. The company was co-founded by Chief Scientific Officer Steven Prestrelski, alongside John Kinzell and Nancy J. Stachowiak, leveraging Prestrelski’s expertise in non-aqueous formulation science. Governance is overseen by Chairperson Marla S. Persky, who took the helm of the board in late 2024. Xeris maintains a strong institutional investor base, with major holdings from BlackRock, Inc. and The Vanguard Group, reflecting market confidence in the company’s path toward sustained profitability and its Phase 3-ready pipeline candidate, XP-8121, for hypothyroidism.